Does Oscar Health Cover Forteo?

What Forteo Is and Why Coverage Matters

Forteo (teriparatide) is a recombinant parathyroid hormone analog that stimulates new bone formation rather than simply slowing bone loss. The FDA approved teriparatide in 2002 for postmenopausal women with osteoporosis at high fracture risk, men with primary or hypogonadal osteoporosis, and patients with glucocorticoid-induced osteoporosis. It is administered as a once-daily 20 mcg subcutaneous injection using a prefilled pen device.

The drug's price makes insurance coverage a practical necessity for most patients. Without insurance, a single Forteo pen (28-day supply) costs roughly $4,100 at retail pharmacies, according to pricing data from GoodRx and CMS drug spending dashboards. Over a full 24-month treatment course, that adds up to nearly $100,000 out of pocket.

Oscar Health, a technology-driven insurer operating in individual marketplace, Medicare Advantage, and small-group segments across more than 20 states, includes Forteo on its formulary. But listing a drug on the formulary and dispensing it without barriers are two very different things. Forteo sits on Oscar's specialty tier, which triggers prior authorization, step therapy, and quantity limits before a single pen ships.

Oscar Health's Prior Authorization Process for Forteo

Oscar requires prior authorization for all anabolic bone agents, Forteo included. Your prescribing physician (typically an endocrinologist or rheumatologist) must submit clinical documentation proving medical necessity. Oscar's utilization management criteria generally align with guidelines from the American Association of Clinical Endocrinology (AACE), which recommend anabolic therapy for patients at very high fracture risk.

The documentation Oscar typically requires includes:

• A DXA scan showing a T-score of <-2.5 at the lumbar spine, femoral neck, or total hip, or a history of fragility fracture.
• Records of an adequate trial (usually 12 months or longer) of at least one oral bisphosphonate such as alendronate (Fosamax) or risedronate (Actonel), with either continued bone loss, a new fracture on therapy, or documented intolerance.
• A statement confirming the patient does not have contraindications to teriparatide, including Paget's disease of bone, unexplained alkaline phosphatase elevation, prior radiation therapy involving the skeleton, open epiphyses, or pre-existing hypercalcemia.
• The intended treatment duration (up to 24 months maximum, per FDA labeling).

Oscar's pharmacy benefits team processes most prior authorization requests within 72 hours for standard reviews. Expedited reviews, reserved for urgent clinical situations, are turned around within 24 hours. If denied, the explanation of benefits letter specifies the exact criterion that was not met, which is critical for structuring an appeal.

Step Therapy: What Oscar Requires Before Approving Forteo

Step therapy is the most common barrier. Oscar, like most commercial insurers, classifies bisphosphonates as first-line treatment and reserves anabolic agents like Forteo for second-line use. This mirrors the treatment sequencing recommended in the Endocrine Society's 2019 osteoporosis guideline, which positions anabolic therapy for patients at "very high" fracture risk or those who fail antiresorptive treatment.

In practice, "failure" means one of three things on Oscar's criteria:

1. A new clinical fracture or significant bone density decline (typically defined as a loss of 3% or more at the spine or hip) after 12 or more months on a bisphosphonate taken with documented adherence.
2. Intolerance to oral bisphosphonates. Esophagitis, severe GI distress, or inability to remain upright for the required 30-minute post-dose interval all qualify.
3. A medical contraindication to bisphosphonates, such as chronic kidney disease with an estimated GFR below 30 to 35 mL/min, where oral bisphosphonates carry risk of further renal impairment.

Patients who present with very high fracture risk at the outset (for example, a recent vertebral fracture plus a T-score of <-3.0) may qualify for step therapy exceptions. The VERO trial (N=1,360) demonstrated that teriparatide reduced new vertebral fractures by 56% compared to risedronate over 24 months in postmenopausal women with severe osteoporosis (relative risk 0.44 to 95% CI 0.29 to 0.68). Citing this trial in a step therapy override request strengthens the clinical case.

What You'll Actually Pay: Copays and Cost-Sharing on Oscar Plans

After prior authorization approval, your cost depends on your specific Oscar plan's benefit design. Oscar categorizes medications into tiers, and Forteo lands on the specialty tier (usually Tier 4 or Tier 5) across marketplace, employer, and Medicare Advantage plans.

Typical cost-sharing structures for specialty-tier drugs on Oscar plans include:

• Marketplace Silver and Gold plans: Copays ranging from $100 to $250 per 28-day fill, or coinsurance of 20% to 33% after the deductible. On a plan with 25% coinsurance, a $4,100 list-price fill costs approximately $1,025 before any manufacturer assistance.
• Marketplace Bronze plans: Higher deductibles mean patients often pay full price until the deductible is met. Once met, specialty coinsurance of 30% to 40% applies.
• Medicare Advantage (Oscar Medicare): Specialty tier copays generally fall between $75 and $150 per fill during the initial coverage phase. After entering the coverage gap (the "donut hole"), patients pay 25% of the drug's cost, which is approximately $1,025 per fill based on benchmark pricing.

One significant cost variable: generic teriparatide. The FDA approved the first generic teriparatide injection in 2023, and several manufacturers now offer it. Generic teriparatide may sit on a lower specialty tier on some Oscar formularies, reducing copays by 30% to 50%. Ask your pharmacist or Oscar's member services team whether the generic is available on your specific plan.

Oscar also applies an annual out-of-pocket maximum. For 2026 marketplace plans, the ACA caps this at $9,200 for individuals and $18,400 for families, according to CMS benefit parameters. Once you hit your plan's out-of-pocket maximum, Oscar covers Forteo at 100% for the remainder of the plan year.

Manufacturer Copay Assistance and the Forteo Savings Card

Eli Lilly, the maker of Forteo, operates a copay savings program for commercially insured patients. Eligible patients with private insurance (including Oscar marketplace and employer plans, but not Medicare or Medicaid) can reduce their monthly out-of-pocket cost to as little as $4 per fill. The program has an annual benefit cap, typically around $10,000 to $12,000 per calendar year.

There is an important catch for Oscar Medicare Advantage members. Federal law prohibits manufacturer copay cards for Medicare beneficiaries. Medicare patients should instead explore the Medicare Extra Help (Low-Income Subsidy) program or state pharmaceutical assistance programs. The Medicare Payment Advisory Commission (MedPAC) reported in 2024 that approximately 30% of Part D enrollees receiving specialty drugs qualified for Extra Help but had not applied.

Dr. Ethel Siris, professor emerita of medicine at Columbia University and a past president of the National Osteoporosis Foundation, has noted: "Financial barriers remain one of the primary reasons patients with severe osteoporosis do not receive anabolic therapy, even when their fracture risk clearly warrants it."

How to Appeal a Forteo Denial from Oscar Health

Oscar denies Forteo requests most often for one of three reasons: insufficient documentation of bisphosphonate failure, missing DXA results, or a step therapy requirement that has not been formally overridden. If your claim is denied, you have the right to appeal.

Oscar's internal appeals process works in two stages. The first-level appeal must be filed within 180 days of the denial. You (or your prescriber acting on your behalf) submit a written appeal with supporting clinical records. Oscar assigns a physician reviewer who was not involved in the original denial decision. Standard appeals receive a decision within 30 calendar days. Expedited appeals, available when delay could seriously jeopardize your health, are decided within 72 hours.

If the first-level appeal is denied, you can request an external review. Under ACA Section 2719, Oscar must allow an independent review organization (IRO) to evaluate the case. The IRO's decision is binding. External reviews are free to the patient.

Tips that increase approval odds on appeal:

• Include a peer-to-peer review request so your physician can speak directly with Oscar's medical director.
• Attach the specific clinical trial data supporting Forteo over bisphosphonates in your clinical scenario. The Neer et al. (2001) key trial (N=1,637) showed teriparatide 20 mcg/day reduced new vertebral fractures by 65% and nonvertebral fractures by 53% compared to placebo over a median 19-month treatment period.
• Reference the AACE/ACE 2020 Clinical Practice Guidelines, which explicitly recommend anabolic-first therapy for patients at very high fracture risk (defined as a recent fracture within the past 12 months, fractures while on approved osteoporosis therapy, multiple fractures, or a T-score below <-3.0).
• Document any adverse events from prior bisphosphonate use with specifics: dates, symptoms, whether the medication was discontinued.

Dr. Michael McClung, founding director of the Oregon Osteoporosis Center, has stated: "The data clearly support anabolic-first sequencing in high-risk patients. Insurers who mandate bisphosphonate failure before covering teriparatide are following an outdated algorithm that increases fracture risk during the wait."

Forteo Alternatives That Oscar May Cover at Lower Cost

If Forteo is denied or cost-prohibitive even after copay assistance, Oscar formularies include several alternatives worth discussing with your prescriber.

Tymlos (abaloparatide): Another anabolic agent, approved by the FDA in 2017. The ACTIVE trial (N=2,463) demonstrated an 86% reduction in new vertebral fractures and a 43% reduction in nonvertebral fractures versus placebo over 18 months. Tymlos faces similar prior authorization and step therapy requirements on Oscar plans, but its formulary tier placement may differ from Forteo.

Prolia (denosumab): A RANK ligand inhibitor given as a subcutaneous injection every six months. Prolia is an antiresorptive, not an anabolic agent, so it works through a different mechanism. The FREEDOM trial (N=7,868) showed denosumab reduced vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% over 36 months. Oscar generally covers Prolia on specialty tier with prior authorization, and copays are often lower because the drug is administered biannually rather than daily.

Evenity (romosozumab): A sclerostin inhibitor with both anabolic and antiresorptive effects, approved for postmenopausal women at high fracture risk. The ARCH trial (N=4,093) showed romosozumab followed by alendronate reduced vertebral fracture risk by 48% compared to alendronate alone over 24 months. Evenity carries a boxed warning about cardiovascular risk and requires even more stringent prior authorization on Oscar plans. It is limited to a 12-month treatment course.

Generic oral bisphosphonates: Alendronate and risedronate remain Tier 1 generics on Oscar formularies, with copays as low as $0 to $10. For patients who have not yet tried these agents, they represent the least expensive option, though they are antiresorptives and do not build new bone the way teriparatide does.

Oscar's Specialty Pharmacy Network and Dispensing

Oscar contracts with specific specialty pharmacies for Forteo dispensing. Most Oscar plans route specialty prescriptions through one or two designated pharmacies, which may include Alto Pharmacy (Oscar's in-house pharmacy partner in some markets) or national specialty networks. You typically cannot fill a Forteo prescription at a retail pharmacy like CVS or Walgreens.

Specialty pharmacy dispensing includes several advantages: temperature-controlled shipping (Forteo must be refrigerated at 2°C to 8°C), adherence monitoring with refill reminders, and nurse-led injection training for patients new to self-injection. Some Oscar plans also include pharmacist check-in calls at 30 and 90 days to monitor side effects like nausea, dizziness, or leg cramps, which the Neer trial reported in 9% to 13% of teriparatide-treated patients.

If you prefer a specific specialty pharmacy, call Oscar member services before your prescriber sends the prescription. Switching pharmacies mid-treatment can cause delays and require a new prior authorization in some cases.

Monitoring Requirements During Treatment

Oscar's coverage terms generally align with the clinical monitoring schedule recommended by the Endocrine Society. Expect your prescriber to order:

• Serum calcium levels within 1 month of starting Forteo. Teriparatide can cause transient hypercalcemia, reported in approximately 11% of patients in clinical trials, though levels rarely exceed clinically significant thresholds.
• A follow-up DXA scan at 12 to 18 months to assess treatment response. Average lumbar spine BMD increases on teriparatide are 9% to 13% over 18 to 24 months, based on data from the Neer key trial.
• Bone turnover markers (serum P1NP or osteocalcin) at 3 months, which can confirm the drug is producing an anabolic response before the DXA shows measurable change.

Oscar covers DXA scans and laboratory monitoring as part of standard medical benefits, separate from the pharmacy benefit that covers the drug itself. These diagnostic services are typically subject to your plan's medical deductible and coinsurance rather than the pharmacy benefit's cost-sharing structure.

After completing the maximum 24-month Forteo course, transition to an antiresorptive agent (a bisphosphonate or denosumab) is essential to preserve the bone density gained. Failure to do so results in rapid bone loss. The DATA extension study showed that patients who stopped teriparatide without antiresorptive follow-up lost nearly all spine BMD gains within 24 months.